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ABSTRACT
The Yes-associated protein, YAP, is a transcriptional co-activator, mediating the 
Epithelial to Mesenchymal Transition program in pancreatic ductal adenocarcinoma 
(PDAC). With the aim to identify compounds that can specifically modulate YAP 
functionality in PDAC cell lines, we performed a small scale, drug-based screening 
experiment using YAP cell localization as the read-out. We identified erlotinib as an 
inducer of YAP cytoplasmic localization, an inhibitor of the TEA luciferase reporter 
system and the expression of the bona fide YAP target gene, Connective Tissue 
Growth Factor CTGF. On the other hand, BIS I, an inhibitor of PKCδ and GSK3β, caused 
YAP accumulation into the nucleus. Activation of β-catenin reporter and interfering 
experiments show that inhibition of the PKCδ/GSK3β pathway triggers YAP nuclear 
accumulation inducing YAP/TEAD transcriptional response. Inhibition of GSK3β by 
BIS I reduced the expression levels of SMADs protein and reduced YAP contribution 
to EMT. Notably, BIS I reduced proliferation, migration and clonogenicity of PDAC 
cells in vitro, phenocopying YAP genetic down-regulation. As shown by chromatin 
immunoprecipitation experiments and YAP over-expressing rescue experiments, BIS 
I reverted YAP-dependent EMT program by modulating the expression of the YAP 
target genes E-cadherin, vimentin, CTGF and of the newly identified target, CD133. 
In conclusion, we identified two different molecules, erlotinib and BIS I, modulating 
YAP functionality although via different mechanisms of action, with the second one 
specifically inhibiting the YAP-dependent EMT program in PDAC cell lines.
INTRODUCTION
The Yes-associated protein, YAP, is a transcriptional 
co-activator containing a proline-rich region responsible 
for the interaction with SH3 domains of c-Yes and 
many other proteins [1]. Multiple post-translational 
modifications (PTMs) regulate the functions of YAP. 
The Hippo signaling pathway, initially defined as a tissue 
growth and organ size regulator in Drosophila, is a kinase 
cascade able to negatively regulate YAP localization 
and activity, by phosphorylating YAP at Serine127. 
Phosphorylation of YAP by the Hippo pathway leads to 
its accumulation in the cytoplasm and, by interaction with 
14–3–3 proteins, YAP is degraded by a ubiquitination-
dependent proteasomal process. Therefore, the Hippo 
pathway negatively regulates YAP functionality and 
presence in the nucleus by modulating its cell distribution 
and its protein expression levels too. Importantly, the 
Hippo pathway-induced phosphorylation of YAP rules 
its functionality according to cell density. At low density, 
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YAP is predominantly localized in the nucleus while 
YAP translocates to the cytoplasm at high cell density 
[2]. Cytoplasmic YAP has been found associated with 
numerous protein complexes that mainly mediate its 
sequestration and consequent functional inactivation. As 
an example, Angiomotins recruit YAP to Tight Junctions 
or the actin cytoskeleton, in a Hippo pathway-independent 
manner, resulting in reduced YAP nuclear localization 
[3,4]. On the same line, when the WNT pathway is off, the 
association of YAP with beta-catenin leads to reciprocal 
inhibition of both proteins [5–7]. GSK3β inhibition 
by 6-bromoindirubin-30-oxime (BIO) promotes the 
activation of YAP via de-activation of the Hippo pathway 
[6]. Nuclear localization of YAP protein is associated with 
its co-transcriptional activity. However, YAP is at the 
crossroad of many signaling pathways, where it plays a 
role depending on the upstream stimuli and the binding 
to its multiple targets. Among the transcription factors 
bound to YAP, members of the TEAD family were found 
to be critical partners of YAP in the regulation of gene 
expression. CTGF has been identified as a direct target 
gene of YAP-TEAD in mammalian cells, and is crucial in 
mediating the growth-stimulating and oncogenic function 
of YAP-TEAD complex [8], but its transcriptional 
expression depends on the contribution from other YAP 
interacting transcription factors such as SMADs [9]. 
Additionally, many other transcription factors have been 
found associated with YAP such as p73 [10], showing 
that YAP can mediate oncosuppressive gene expression 
program according to the cell context. Several pieces of 
evidence support an important role of YAP in different 
types of cancer [11,12], pancreatic ductal adenocarcinoma 
(PDAC) included [13,14]. Indeed, YAP expression, via 
immunohistochemistry studies in pancreatic tumor tissues, 
was reported as moderate to strong in the nucleus and 
cytoplasm of the tumor cells compared to adjacent normal 
tissues. In cell lines, YAP localization was modulated by 
cell density and its genetic ablation led to a decrease of 
growth in soft agar of pancreatic cancer cells [12,13]. 
In PDAC mouse models, YAP has been shown to be an 
essential promoter of mutant KRAS oncogenic program, 
specifically inducing the expression of secreted factors 
as CTGF and CYR61 [15] and associating with FOS to 
regulate the expression of Epithelial to Mesenchymal 
Transition genes as E-cadherin, SLUG, SNAIL and 
Vimentin [16]. These pieces of evidence suggest a role of 
YAP in pancreatic cancer development, potentially playing 
an important role in the Epithelial to Mesenchymal 
Transition (EMT) of pancreatic cancer cells. Therefore, 
the identification of inhibitors of YAP activity could be 
suitable as a new therapeutic option for PDAC treatment.
However, an intricate network of signaling pathways 
contributes to EMT in PDAC. TGFβ signaling pathway is 
frequently genetically altered in PDAC [17], and the “late 
TGFβ signature” [18] actively promotes late EMT also 
cooperating with YAP [9] and activating the RAS-ERK 
pathway promoting the expression of EMT transcription 
factors such as SNAIL and ZEB1 [19]. CD133 is a well-
known cancer stem marker [20] which has been included 
to the plethora of genes responsible for EMT promotion by 
activating SRC pathway [21–23].
We performed a small-scale high-content screening 
for the identification of compounds able to interfere 
with YAP localization and functionality. This approach 
allowed us to assign to the widely used Receptor Tyrosine 
Kinase (RTK) Inhibitor, erlotinib, the ability to sequester 
YAP into the cytoplasm blocking its co-transcriptional 
function. Additionally, we found that a small molecule, 
GF 109203X (BIS I), induces YAP nuclear accumulation 
and activation, however, modulating its co-transcriptional 
activity by blocking the YAP-dependent EMT program 
downregulating SMAD2/3.
RESULTS
YAP regulates anchorage-independent growth 
in PDAC cell lines
We measured the expression level of YAP in a 
panel of four PDAC cell lines using western blotting 
and qRT-PCR: PANC1 and PK9 exhibited moderate to 
high YAP protein levels, respectively, in comparison to 
BXPC3 and MIAPACA2 cells (Figure 1A). Cell density 
regulates phosphorylation and localization of YAP via 
the Hippo signaling pathway. High cell density predicts a 
cytoplasmic YAP localization while YAP appears mainly 
localized in the nucleus in sparse cell culture of breast 
cancer cells [24]. We investigated whether cell density 
regulates YAP localization in pancreatic cancer cells. We 
assessed the expression level and localization of YAP at 
different cell densities using immunofluorescence in PK9 
and PANC1 cells. Sub-cellular distribution of YAP protein 
was equivalent in both cases with PANC1 cells, but YAP 
significantly shuttled from nucleus to the cytoplasm at high 
cell density in PK9 cells, as determined by high content 
imaging analysis (Figure 1B). To investigate the functional 
role of YAP, we interfered YAP expression in PK9 and 
PANC1 cells using lentiviral transduction of specific 
shRNA (Supplementary Figure S1A). shYAP-PANC1 and 
shYAP-PK9 cells showed a decrease of 90% and 40% of 
YAP mRNA compared to (SCR) control cells, respectively 
(Figure 1C). CTGF and Cyr61 mRNA expression, bona 
fide YAP targets, were significantly reduced in shYAP-
PANC1 and shYAP-PK9 (Figure 1C), whereas other 
targets like AREG and BIRC5 were distinctly up-regulated 
in silenced cells, indicating a transcriptional impact due 
to YAP modulation. On the other hand, CTGF expression 
was found increased in the case of YAP overexpression 
(O/E) both in PK9 and in PANC1. CYR61 expression was 
increased in PK9 O/E YAP. (Figure 1D). Phenotypically, 
both YAP stable silencing (shYAP) and its transient 
functional ablation inhibited anchorage-independent 
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Figure 1: Importance of YAP in PDAC cell lines. A. YAP is expressed in PDAC lines at different levels. Western blot analysis 
of endogenous level of YAP in PDAC cell lines and qRT-PCR analysis of YAP mRNA expression. The relative intensity of the bands 
(left) and YAP mRNA level (right) are shown. B. Localization of YAP is regulated by cell density in PK9. PK9 and PANC1 cells were 
cultured sparsely (LOW) and densely (HIGH) onto glass cover slides (Left panel) and in 96 well-plate (right panel) for 48H. Cells were 
fixed and nuclei were counterstained with DAPI. The localization of YAP was visualized using a Zeiss Observer Z1 microscope equipped 
with Apotome module, with a Plan Apochromatic (63X, NA 1.4) objective. Images were acquired using Zen 1.1 (blue edition) imaging 
software (Zeiss) and assembled with Adobe Photoshop CS3 (Left panel). Quantitative analysis of sub-cellular localization of YAP was 
quantified using Operetta instrument and Harmony 3.5.2 software. Ratio of YAP Nuc/Cyto is shown. (*p<0.05). C. YAP functional 
ablation down-regulates CTFG and CYR61 but not AREG and BIRC5 mRNA levels. PANC1 (left) and PK9 cells (right) were stably 
transduced with a lentiviral vector encoding shRNA targeting YAP or a non-targeting control shRNA (SCR). After stable selection with 
puromycin, the relative levels of endogenous YAP and its target genes, CTGF, CYR61, AREG and BIRC5 mRNA were measured by 
qRT-PCR (mean±SD). (**P<0.0, **P<0.01 versus SCR). D. Overexpression of YAP increases CTGF and CYR61 levels in PK9 cells. 
PK9 and PANC1 cells were transiently transfected with pEGFP-YAP or empty vector (pEGFPN1) for 24H. Overexpression of YAP 
was confirmed by qRT-PCR analyses. The expression levels of CTGF and CYR61 were then evaluated. E. YAP functional ablation 
attenuates anchorage-independent growth in soft agar. PANC1 cells were stably transduced with a lentiviral vector encoding shRNA 
targeting YAP or a non-targeting control shRNA (SCR). These clones (1.5x104 cells) were seeded in 0.35% agar (top agar) medium in 
6 well-plates coated with 0.7% agar (based agar) for 2 weeks. Total colony number and colony diameter were measured using Operetta 
and Harmony 3.5.2 software (below).
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growth of PANC1 cells in soft agar (Figure 1E) and 
slowed their proliferation rate (Supplementary Figure 
S1B), in good agreement with previous data [14, 25]. 
Therefore, in PDAC cell lines cultured at high-density, 
YAP is partially redistributed in the cytoplasm, it has a 
transcriptional effect controlling the expression of known 
target genes, it regulates proliferation and the ability of 
PDAC cells to grow in anchorage-independent conditions.
Identification of modulators of YAP localization
To gain further insight into the molecular players 
regulating YAP localization, we performed a small-scale 
nucleo-cytoplasmic high content assay to quantify YAP 
protein subcellular localization in PDAC cells. As a 
cell model, we used PK9 cells as YAP was re-localizing 
into the cytoplasm at high cell density (Figure 1B). We 
used a library of 80 characterized kinase inhibitors (see 
methods) with the aim to find molecules that could 
modulate accumulation of YAP in the cytoplasm or the 
nucleus, to identify the signaling cascade responsible 
for these subcellular re-localizations and the biological 
effects caused by its sub-cellular re-distribution. Most 
of the molecules did not affect YAP localization being 
the Z-score values of the nuclear/cytoplasmic intensity 
close to controls (Figure 2A, Table 1, Supplementary 
Table S1). Few compounds were further increasing 
cytoplasmic YAP compared to control, and only two 
compounds led to significant YAP accumulation into the 
nucleus. Interestingly, first hits among YAP cytoplasmic 
accumulators were inhibitors of tyrosine kinase receptors 
(RTKIs) such as Genistein and Tyrphostins and one 
inhibitor of the RAS pathway as ZM336372. On the other 
hand, inducers of YAP nuclear shuttling were BIS I and Ro 
31-8220, two representatives of the bisindolylmaleimide 
family of Ser/Thr kinase inhibitors, as PKCs (Table 1).
Cytoplasmic inducers marginally modulate 
YAP co-transcriptional activity
As the receptor tyrosine kinase inhibitors identified 
belong to the family of tyrphostin [26], precursors of 
the more potent and clinically used inhibitors of RTKIs, 
such as erlotinib and lapatinib, we decided to use these 
two drugs for further investigation. Moreover, given 
the importance of the constitutive activation of the 
RAS pathway in PDAC [27], we also evaluated the 
efficacy of ZM336372 in inhibiting YAP-dependent 
transcriptional effects by using TEA luciferase reporter 
system as a readout. Only erlotinib inhibited modestly, 
but significantly, TEA reporter and reduced the expression 
level of CTGF but with no efficacy on Cyr61 (Figure 2B, 
2C). On the contrary, lapatinib and ZM336372 increased 
CTGF and Cyr61 expression levels (Figure 2C). Summing 
up, only erlotinib showed a minimal, although significant, 
negative modulation of YAP co-transcriptional activity.
BIS I changes YAP co-transcriptional activity 
and inhibits anchorage independent growth
Bisindolylmaleimide chemical family of compounds 
are strong inhibitors of several kinases in the nanomolar 
range and, therefore, it is difficult to associate a molecular 
target directly to its efficacy. BIS I is a cell-permeable 
and reversible inhibitor of protein kinases C (PKCs) 
both conventional and atypical, but also of GSK3β 
[28]. Moreover, compounds of the same class show 
differential selectivity towards the same serine/threonine 
kinases. For example, Go9676 was reported to be more 
specific for PKCα than for PKCδ [29], while BIS I 
behaves oppositely [30]. Since bisindolylmaleimides are 
fluorescent compounds and could have interfered with 
the immunofluorescence-based screening, we performed 
nuclear/cytoplasmic separation and Western blots analyzes 
of YAP levels upon drug treatments. We observed that 
BIS I induced YAP nuclear localization in PDAC cell 
lines, confirming the indication coming from the HCS 
experiment (Figure 2D). Then we evaluated the stability 
of YAP protein during BIS I treatment, and, in the time 
frame of 48 hours, YAP protein was stable, suggesting 
that we observed a pure subcellular re-localization 
not affected by changes in protein expression level 
(Supplementary Figure S1C). During re-localization, the 
YAP post-translation status was deeply changed, as many 
phosphorylation spots were present in the two-dimensional 
western blots (Figure 2E). Hippo signaling pathway was 
not directly involved in the observed PTMs because the 
phosphorylation state of YAP-S127 and LATS-S909 
did not change (Figure 2F). Additionally, we observed 
a decrease in the expression level of LATS protein, an 
effect that is likely independent of the activation of the 
Hippo signaling but might contribute to the translocation 
of YAP into the nucleus. BIS I amplified TEA reporter 
signal in the basal conditions in PANC1 cells and during 
YAP overexpression both in PK9 and PANC1 cells 
(Figure 3A) and induced TEA reporter signal reduction 
during functional ablation of YAP. Therefore, the effect 
of BIS I on TEA reporter depends on the presence of 
YAP (Figure 2B, 3A). Unexpectedly, BIS I significantly 
suppressed CTGF and Cyr61 mRNA expression and 
slightly increased AREG and BIRC5 mRNA expression in 
PK9 and PANC1 cells at 24 hours of treatment, mimicking 
YAP ablation (Figure 3B). To evaluate if BIS I displaces 
YAP from CTGF promoter, despite YAP presence in the 
nucleus, we performed chromatin immunoprecipitation 
of YAP and evaluated the amplification of the CTGF 
promoter [31]. Indeed, YAP was no more associated 
with the CTGF promoter during BIS I treatment, but 
TEAD1 was still present (Figure 3C). Additionally, we 
observed that BIS I inhibited TGF-β induced CTGF 
expression in a YAP independent manner but activated 
TEA reporter in a TGF-β independent manner (Figure 4A 
and Supplementary Figure S1D). BIS I treatment reduced 
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the expression level of SMAD2/3 mRNAs and proteins 
in a YAP independent manner (Figure 4A, Figure 4B, 
Supplementary Figure S1E). BIS I phenocopied the 
effects of YAP functional ablation: it slowed down cell 
proliferation and induced an accumulation in the S-phase 
(Supplementary Figure S1B, S1F). Most importantly, 
BIS I was readily effective in reducing the anchorage-
independent growth of PDAC cell lines. Among the four 
cell lines tested, PANC1 and MIAPACA2 formed colonies 
within two weeks, while PK9 took longer and we could not 
detect BXPC3 colony formation. BIS I reduced the total 
number of colonies of PANC1, MIAPACA2, and PK9 and 
reduced the colony dimensions of PANC1 and PK9 but 
increasing MIAPACA2 ones (Figure 4C). Summing up, 
Figure 2: Identification of modulators of YAP localization. A. High-content screening evaluating YAP localization. A kinase 
inhibitor’s library was administrated to PK9 cells using a high-throughput approach (1μM, 24H). The ratio between nuclear and 
cytoplasmic regions was calculated and normalized to untreated controls. The Z-score was reported in a graph, positive and negative 
values indicate nuclear accumulation and cytoplasmic localization, respectively. Fixed cells were incubated with antibody against YAP 
and DAPI staining. Sub-cellular localization of endogenous YAP protein was detected by Operetta and analyzed with Harmony 3.5.2 
software. B. Modulation of TEA reporter by hit compounds. PK9 cells were transiently co-transfected with pEGFPN1 or YAP, TEA 
reporter (8xGTIIC-Luc reporter), and Renilla luciferase to record YAP/TAZ-dependent transcriptional activity. Cells were then treated 
with different compounds for 24 H and the firefly luciferase signals were normalized to the ones of Renilla luciferase. Data are globally 
normalized to MOCK and are presented as mean±SD. C. Modulation of CTGF and CYR61 by hit compounds. The panel represent qRT-
PCR for YAP/TAZ target genes CTGF and Cyr61, relative to GAPDH expression. PK9 cells were treated with 5μM of different compounds 
and data, normalized to MOCK, are presented as mean±SD. (*p<0.05 and **p<0.01). D. BIS I induces YAP nuclear accumulation. 
Western blot analysis of nuclear fraction and cytosolic fraction of YAP in PK9 and PANC1 cell lines after treatment with 1μM and 10μM 
of BIS I for 24H. The relative intensities of the bands are also shown (right). Data are normalized to MOCK and presented as mean±SD. 
(*p<0.05 and **p<0.01). E. BIS I induces YAP post-translational modifications. Filters were blotted with antibodies against YAP and 
YAP Ser127-P. As negative control for phosphorylation the treated sample was incubated with calf intestinal alkaline phosphatase (CIAP). 
As positive control for phosphorylation at Ser127, cell lysates from high density culture was used. F. BIS I does not affect the Hippo 
pathway. Western blot analysis of an upstream regulator of YAP, LATS1 and its phosphorylated form (Ser909). PK9 cells were treated 
with BIS I 10μM for 24 H. Phosphorylation of YAP and LATS1 was measured by western blot. The relative intensities of the bands were 
normalized to β-actin levels (right).
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BIS I induced YAP into the nucleus and triggered TEAD 
response; however, it inhibited anchorage-independent 
cancer cell growth and proliferation, phenocopying YAP 
ablation and inhibiting TGFβ-dependent cell response by 
decreasing the expression of SMADs and SMAD/YAP co-
regulated genes.
CD133 gene expression is regulated by YAP 
and inhibited by BIS I
To further investigate the molecular mechanism 
of bisindolylmaleimides leading to YAP nuclear 
accumulation, we evaluated four of them for their ability 
to modulate CTGF expression levels. BIS I and BIS II 
reduced CTGF expression in PK9 and PANC1 cells, 
although to a different extent, while Go9676 increased 
CTGF expression. BIS IV showed an increase of CTGF 
expression only in PK9 cells with no activity in the 
other cell lines (Supplementary Figure S2A). None of 
the bisindolylmaleimides tested showed toxic effects 
(Supplementary Figure S2B). Given the relative specificity 
of BIS I for PKCδ/GSK3β, while Go9676 is more specific 
for PKCα, we hypothesized that PKCδ/GSK3β ablation 
could phenocopy BIS I treatment. Transient silencing of 
PKCδ and GSK3β showed that CTGF decreased in both 
cases linking the activity of these two kinases in CTGF 
expression regulation (Figure 4D, Supplementary Figure 
S2C). Short-term treatment with the GSK3β inhibitor LiCl 
induced the expression of CTGF mRNA, but long-term 
treatment decreased CTGF expression [32]. Interestingly, 
the downregulation of SMAD2 mRNA occurred only at 
a late time point whereas SMAD3 was already down-
regulated at 6 hours (Supplementary Figure S2D). BIS I 
induced the downregulation of both SMADs already at 6 
hours. Silencing of GSK3β activated TEA reporter only 
in the presence of YAP overexpression, similarly to BIS 
I treatment (Supplementary Figure S2E) and reduced 
the expression of SMAD3 mRNA (Figure 4E) as BIS I 
treatment. Since the association of YAP to the destruction 
complex has been reported [5], we evaluated the activation 
of the WNT/β-catenin signaling in PDAC cell lines 
during BIS I treatment. We performed a reporter assay 
with a construct expressing luciferase under the control 
of tandem repeats of TCF binding site (TOPFlash) or a 
mutated one (FOPFlash). BIS I strongly activated WNT/β-
catenin reporter activity in all of the PDAC cell lines used 
and in HEK293T cells (Figure 5A, Supplementary Figure 
S2F) as well as induced the accumulation of β-catenin 
in the nucleus (Figure 5B). Coherently, Go9676 did not 
activate TCF/LCF reporter nor induced β-Catenin into the 
nucleus (Figure 5A, 5B).
Given the importance of YAP and β-Catenin in 
regulating differentiation, we investigated if BIS I could 
affect the expression levels of stemness markers of PDAC. 
In our case, pancreatic stemness gene CD133 was up-
regulated upon β-Catenin over-expression (Figure 5C). 
These stemness genes were down-regulated during BIS I 
treatment (Figure 5D), but, interestingly, only CD133 was 
affected by YAP and GSK3β ablation (Figure 5E and 5F). 
Moreover, YAP overexpression induced the up-regulation 
of CD133 that was blocked by BIS I (Figure 5G), therefore 
identifying CD133 as a new gene regulated by YAP and 
GSK3β. To sum up, BIS I induced YAP and β-Catenin 
nuclear accumulation by inhibiting the PKCδ/GSK3β 
pathway. Moreover, BIS I treatment decreased the level 
of cancer stem cell markers, but only the effect on CD133 
could be ascribed to a loss of YAP functionality. Notably, this 
gene is a new critical regulator of EMT in PDAC [21,23].
Table 1: Hits from High-Content Screening 
Z-score Molecule Molecular Target
YAP Nuclear Accumulators
0.915 GF 109203X PKC
0.971 Ro 31-8220 PKC
YAP Cytoplasmic Accumulators
1.382 Tyrphostin AG 1295 Tyrosine kinases
1.355 ZM 336372 cRAF
1.238 Genistein Tyrosine Kinases
1.182 N9-Isopropyl-olomoucine CDK
1.18 SP 600125 JNK
1.171 AG-1296 PDGFRK
1.169 Kenpaullone GSK3β
1.132 AG-494 EGFRK, PDGFRK
Lower values indicate higher nuclear accumulation, higher values indicate higher cytoplasmic accumulation
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Figure 3: BIS I treatment phenocopies YAP functional ablation. A. BIS I modulates TEA reporter in YAP-dependent 
manner. Left panel: BIS I activates TEA reporter activity. PK9 and PANC1 cells were transiently co-transfected with YAP (O/E YAP) or 
without YAP (pEGFPN1) and TEA reporter (8xGTIIC-Luc reporter), then treated with BIS I 5μM for 24H. Right panel: YAP is required 
for TEA reporter activation. Stably YAP silenced PANC1 cells were co-transfected with TEA reporter (8xGTIIC-Luc reporter) or its 
empty vector (pGL4), and Renilla. The firefly luciferase signals were normalized to the ones of Renilla. (mean±SD from biological 
triplicates) (*p<0.05 and **p<0.01 versus MOCK of PK9 and #p<0.05 and ##p<0.01 versus MOCK of PANC1). B. BIS I modulates 
YAP target genes. PK9 (left panel) and PANC1 (right panel) cells were treated with 5μM BIS I for 24H. Quantitative RT-PCRs of CTGF, 
Cyr61, BIRC5, AREG, YAP/TAZ target genes and YAP relative to GAPDH expression with respect to MOCK are presented as mean±SD. 
(*p<0.05 and **p<0.01 versus MOCK). C. BIS I displaces YAP from CTGF promoter. Map of CTGF promoter region with positions 
of the two primers used for ChIP analysis. TSS indicates the transcription start site, while TRE indicate the previously identified TEAD 
responsive elements. Chromatin immunoprecipitation (ChIP) at CTGF promoter was performed using antibodies against YAP, TEF-1 and 
IgG as negative control. After DNA extraction and qRT-PCR, results were normalized to non immunoprecipitated sample (INPUT) and 
compared to IgG for statistical significance. BIS I was able to reduce the DNA enrichment observed for YAP, whereas it was ineffective 
against TEF-1 DNA-binding protein.
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YAP-dependent EMT transcriptional program is 
inhibited by BIS I
EMT signature, in PDAC, in mainly driven by the 
activation of the RAS pathway in association with the 
transcriptional program induced by FOS, SMADs, and 
YAP [16] and the loss of E-cadherin is a major event during 
EMT [22]. Our cell lines exhibit different expression levels 
of E-cadherin (Figure 6A, 6B). PK9 and BxPC3 cell lines 
showed high protein level of E-cadherin whereas PANC1 
and MIAPACA2 had low to undetectable E-cadherin protein 
levels (Figure 6A). This expression profile of E-cadherin 
in PDAC is consistent with its mRNA levels (Figure 6B). 
Our results show that endogenous levels of E-cadherin 
are inversely correlated with the anchorage-independent 
growth ability of these PDAC cell lines (Figure 4C). 
Importantly, EMT signature was dependent on YAP as, in 
shYAP-PK9 and shYAP-PANC1, E-cadherin and CD133 
expression was reverted (Figure 6C, Figure 5E, 5G). During 
BIS I treatment, the clonogenic and migration abilities of 
Figure 4: The CTGF expression level was modulated by the TGF-β and Hippo pathways in PDAC. A. BIS I inhibits 
TGF-β induced CTGF expression and reduces SMAD2/3 gene expression levels. PK9 cells were stably transduced with a lentiviral 
vector encoding shRNA targeting YAP (shYAP) or a non-targeting control shRNA (SCR). They were then treated with BIS I 5μM in the 
presence and absence of TGF-β 50ng/ml for 24H. The expression levels of CTGF, SMAD2 and SMAD3 were then evaluated. (*p<0.05 and 
***p<0.001 versus MOCK). B. BIS I down-regulated Smad2/3 protein levels. PK9 cells were seeded and treated with BIS I 10μM for 
24H. The endogenous protein level of Smad2/3 was evaluated by western blotting against Smad2/3 antibody. The relative intensities of the 
bands normalized by β-actin are shown below. (***p<0.001 versus MOCK). C. BIS I inhibits anchorage-independent growth of PDAC. 
PDAC (1.5x104 cells) were seeded on 0.35% agar (top agar) culture medium in 6 well-plated coated with 0.7% agar (based agar). Cells were 
treated with BIS I 10μM for 2 weeks. Total colony number and colony diameter were measured using Operetta instrument. D. The CTGF 
expression level was modulated by PKCδ and GSK3β in PK9 cells. PK9 cells were incubated with siRNA targeting PKCδ, GSK3β, and 
non-targeting control (SCR) for 72H. Quantitative RT-PCRs of CTGF relative to GAPDH expression with respect to SCR are presented as 
mean+SD. (*p<0.05 and **p<0.01 versus SCR). E. Genetic ablation of GSK3β suppresses SMAD expression levels in PK9. PK9 cells 
were incubated with siRNA targeting GSK3β, and non-targeting control (SCR) for 72H. Quantitative RT-PCRs of CTGF relative to GAPDH 
expression with respect to SCR are presented as mean+SD. (***p<0.01 versus SCR).
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PDAC, markers of EMT, were completely inhibited (Figure 
4C, 7A). BIS I was able to revert the EMT signature by 
restoring E-Cadherin expression, as well as by regulating 
other EMT markers as vimentin, ZEB1 and CD133 also in 
the presence of TGFβ (Figure 5G, 7B, 7C, 7D). Migration 
of PANC1 cells decreased by administration of BIS I 
in sh-YAP PANC1 cells at 48 hours (Figure 7A). More 
notably, the effect of BIS I on the modulation of CTGF, 
E-cadherin, vimentin, and CD133 was rescued by YAP 
overexpression showing that BIS I mechanism of action 
Figure 5: BIS I activates β-catenin and downregulates the expression level of cancer staminality genes. A. BIS I activates 
β-catenin signaling pathway. β-catenin induced activation of TOP-flash (TCF/LEF) luciferase reporter was performed in HEK293T and 
PDAC cells lines. Cells were co-transfected with TOP-flash luciferase reporter and in the presence and absence of β-catenin. BIS I and 
Go6976 5μM were used for 24H treatment after transfection. Data are presented as average fold induction relative to MOCK. (*p<0.05 
and **p<0.01). B. BIS I modulates β-catenin nuclear localization. Western blot analysis of nuclear fraction and cytosolic fraction 
of β-catenin in PK9 cells after treatment with BIS-I and Go6976 10μM for 24H. The relative intensities of the bands are shown below. 
The relative intensities of the bands was normalized by β-actin and lamin A/C for cytosolic and nuclear protein levels, respectively. 
C. β-catenin regulates CD133 expression. PK9 cells were transiently transfected with indicated β-catenin plasmid for 24H. Quantitative 
RT-PCRs of CD133 and OCT4 relative to GAPDH expression with respect to MOCK are presented as mean±SD. (*p<0.05 and **p<0.01). 
D. BIS I inhibits expression of staminality markers in PK9. PK9 cells were treated with BIS I 5μM for 24H and expression levels 
of ABCG2, CD133, MUL1, OCT4, PAX6, and SOX2 were analyzed by qRT-PCR relative to GAPDH expression. Data are presented as 
mean±SD. (**p<0.01 versus MOCK). E. Genetic ablation of YAP down-regulates CD133 expression. Stemness markers were measured 
by qRT-PCR in stably YAP silenced PK9 cells. Data are presented as mean±SD. (**p<0.01 versus SCR). F. Genetic ablation of GSK3β 
down-regulates CD133 expression. PK9 cells were incubated with siRNA targeting GSK3β, and non-targeting control (SCR) for 72H. 
Quantitative RT-PCRs of CD133 relative to GAPDH expression with respect to SCR are presented as mean±SD. (***p<0.01 versus SCR). 
G. BIS-I treatment reverts the CD133 up-regulation induced by YAP overexpression. PK9 cells were transiently co-transfected with 
indicated plasmids (YAP and pEGFPN1) and in the presence and absence of BIS I treatment for 24H. CD133 expression was measured by 
qRT-PCR. Data are presented as mean±SD. (*p<0.05 and **p<0.01 versus MOCK).
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relies on the inhibition of the EMT-related, YAP-dependent 
transcriptional program (Figure 5G, 7D). In sum, we show 
that BIS I inhibits EMT in PDAC cell lines triggering the 
expression of epithelium markers by down-regulating 
SMAD2/3 and blunting YAP co-transcriptional activity.
DISCUSSION
In this study, we show that BIS I, an inhibitor of the 
PKCδ/GSK3β pathway, reverts the EMT transcriptional 
program in PDAC cell lines inhibiting the TGFβ pathway 
and de-potentiating YAP contribution to EMT via down-
regulation of SMAD2/3.
In agreement with previous reports [14,33,34], 
we observed that, in PDAC cell lines, YAP mainly 
regulates anchorage-independent growth, migration, and 
proliferation. However, YAP governs the expression of 
only some of the bona fide YAP target genes in these cell 
lines as only CTGF and CYR61, but not AREG or BIRC5, 
decreased during YAP functional ablation. Indeed, in a 
KRAS mutant context, YAP, being post-translationally 
modulated by KRAS/MAPK signaling cascade, promotes 
Figure 6: BIS I reverts YAP-induced EMT in PDAC cell lines. A. Endogenous protein level of E-cadherin in PDAC cell 
lines. Western blot analysis of endogenous level of E-cadherin in PDAC cell lines. B. Expression level of E-cadherin mRNA in PDAC 
cell lines. qRT-PCR analysis of CDH1 mRNA expression was performed in PDAC cell lines. C. Both genetic ablation of YAP and BIS I 
treatment induce E-cadherin expression levels. SCR or stably YAP-silenced PK9 and PANC1 cells were treated with BIS I 5μM for 24H. 
Western blot analysis of endogenous level of YAP and E-cadherin was performed. The relative levels of endogenous E-cadherin protein 
(left) and mRNA levels from these lysates (right) were evaluated by immunoblot and qRT-PCR, as shown below.
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the expression of pro-proliferative secretory factors as 
CTGF and CYR61, preferentially [15]. From our small-
scale screening of kinase inhibitors, using as reporter 
system the localization of the endogenous YAP protein, 
we found out that general inhibitors of RTKs and one RAS 
inhibitor induced YAP accumulation into the cytoplasm. 
This finding suggests a functional link between the 
EGFR and RAS pathway and YAP activity as observed 
in Drosophila [35], liver carcinoma [36], NSCLC cells 
[37] and pancreas itself [16]. Unfortunately, none of these 
inhibitors was potent enough to inhibit TEA reporter 
system and decrease CTGF expression, suggesting that 
the residual amount of nuclear YAP was still active. 
Only erlotinib showed a small but significant trend 
towards inhibition of YAP co-transcriptional activity. 
Indeed, erlotinib arrests NRG1-ERBB4-YAP signaling 
in breast cancer cell lines [38], and suggests a further 
rationale for the utilization of erlotinib in PDAC [39]. 
Additionally, we found of interest the behavior of YAP 
nuclear accumulators, i.e. bisindolylmaleimides. The 
mechanistic explanation can be linked to the pleiotropic 
effect of BIS I. One possibility is that BIS I induced arrest 
of the proteasome leading to accumulation of β-catenin 
[40, 41] and YAP, being both proteins targeted for 
degradation. Alternatively, the BIS I induced inhibition 
of PKCδ/GSK3β activity can lead to the degradation of 
the destruction complex as proved by β-catenin and YAP 
nuclear accumulation. Inhibition of the GSK3β by BIS 
I led to osteogenic differentiation and suppression of 
adipocyte differentiation by β-catenin stabilization [42, 
43]. More importantly, these data are in agreement with the 
inhibition of the GSK3β by BIO that led to the activation 
of YAP/TEAD response [6]. We did not observe a clear 
inactivation of the Hippo pathway but a down-regulation 
Figure 7: Genetic ablation of YAP and BIS I treatment regulate cell migration. A. BIS I reduces cell migration synergizing 
with YAP silencing. Scratch assay was performed in SCR or stably YAP-silenced PANC1 cells. Images of invaded cells at 0, 24, and 48 H 
after scratching and treatment with BIS I were taken from a time-lapse sequence of PANC1 cell migration; wounds with consistent shape 
within each well were generated using 200 μl tip. Percentage of invaded cells at different time point is indicated (right panels) as calculated 
by ImageJ softwre. (*p<0.05 and **p<0.01). B. BIS I down-regulates VIM and ZEB1 mRNAs. PK9 cells were treated with BIS I for 
24H. Expression level of VIM and ZEB1 were measured by qRT-PCR. Data are presented as mean±SD. (**p<0.01 versus MOCK). C. BIS 
I inhibits TFG-β induced ZEB1 expression. PK9 cells were stably transduced with a lentiviral vector encoding shRNA targeting YAP 
(shYAP) or a non-targeting control shRNA (SCR). They were then treated with BIS I 5μM in the presence and absence of TGF-β 50ng/
ml for 24H. The expression levels of ZEB1 was evaluated. (*p<0.05, **p<0.01 and ***p<0.001). D. Overexpression of YAP reverts the 
effect of BIS-I on the expression of CTGF, CDH1 and VIM. PK9 cells were transiently co-transfected with YAP and pEGFPN1 plasmids 
and treated with BIS I for 24H. CTGF, CDH1, VIM, and ZEB1 expression levels were measured by qRT-PCR. Data are presented as 
mean±SD. (*p<0.05 and **p<0.01).
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of LATS that explains the nuclear translocation of YAP, 
also in an independent manner from the association 
to the destruction complex [6]. Indeed, we observed 
the activation of the TEA reporter system during BIS I 
treatment, but, at the same time, a clear, YAP-dependent, 
decrease of CTGF and CYR61 mRNAs. CTGF promoter 
region is highly regulated, and several transcription factors 
contribute to the activation of this locus. In mesangial and 
gingival cells, BIS I blockage of basal and TGFβ-induced 
regulation of CTGF [44,45] was explained by inhibition 
of GSK3β. Moreover, in hepatocarcinoma cells, PKCδ-
mediated TGFβ signaling led to CTGF expression by 
inhibiting the phosphatase PPM1A, which is responsible 
for the SMAD2/3 inactivation [46]. Downregulation of 
CTGF upon functional ablation of PKCδ and GSK3β 
highlights that the similar mechanisms occur in PDAC 
cell lines (Figure 4D) and can be explained by SMAD3 
mRNA downregulation (Figure 4E). GSK3β inhibition 
by LiCl induces a biphasic CTGF expression regulation: 
an initial burst of expression, coherent with YAP nuclear 
accumulation, is followed by a long-term downregulation 
of the gene. This secondary response is likely due to the 
parallel downregulation of SMAD2/3 (Supplementary 
Figure S2D, S2E). BIS I down-regulated CTGF and 
SMAD2/3 already at 6 hours, therefore showing a strong 
potency in blocking TGFβ in a SMAD4 deficient context, 
a frequent lesion in PDAC [47] and our cell lines. The 
same mechanism applies to YAP/SMADs co-regulated 
genes and, given the importance of this association in 
promoting EMT [48], it explains the specific reversion of 
EMT markers. Therefore, the down-regulation of SMADs 
dampens the YAP co-transcriptional activity of EMT 
genes. Indeed, YAP overexpression rescued phenotypically 
the ability to migrate and grow in anchorage-independent 
condition, and, molecularly, it inhibited the re-expression 
of E-cadherin and blunted the downregulation of CTGF, 
CD133, and Vimentin. Additionally, we showed that BIS 
I induced displacement of YAP from CTGF promoter, 
showing a loss of function of nuclear YAP on specific 
genes, likely driven by the loss of SMADs partner. Finally, 
we observed that BIS I induced the downregulation of 
many cancer stem genes, CD133 included, and we found 
that this new marker of EMT is highly regulated as YAP, 
GSK3β, and β-catenin modulated CD133 expression, 
addressing this gene as a co-regulated gene by these three 
factors. Further experiments are necessary to clarify this 
point. However, it suggests that inhibition of the SRC 
pathway via dasatinib [23,49] may influence EMT in 
PDAC by modulating YAP activity.
MATERIALS AND METHODS
Antibodies, plasmids and reagents
The following antibodies were used: Anti-YAP (sc-
101199), anti TEF-1 (sc-376113), Anti-GSK3β (sc-9166), 
Anti phospho GSK3β Ser9 (sc-11757), Anti β-catenin (sc-
7199) (Santa Cruz Biotechnology). Anti-Lats1 (3477), 
Anti-phospho Lats1 Ser909 (9157), Anti-Smad2/3 (8685) 
and Anti-phospho-YAP (S127) (4911), Anti β-actin (3700) 
(Cell Signaling). Alexa Fluor 488-conjugated secondary 
antibodies (Invitrogen). The chemicals were used in this 
study: GF 109203X (B6292), Go6976 (G1171), phorbol 
12-myristate 13-acetate (PMA) (Sigma, P1585) were 
purchased from sigma. Lapatinib (S1028), Erlotinib 
(S1023) were purchased from Selleckchem. Recombinant 
human transforming growth factor 1 (TGF-β) (PHG9204) 
was purchased from Life technologies. The plasmids 
were used: 8xGTIIC-luciferase (#34615), YAP-GFP 
(12), pEGFP-N1 (Clontech), pGL4 (Promega), human 
B-catenin pcDNA3 (#16828), c-Flag pcDNA3 (#20011), 
TOP flash and FOP flash were gifted from Dr. Arthit [50].
Cell culture and transfections
Human pancreatic carcinoma cell lines (PK9, 
MIAPACA2, PANC1, BxPC3) were kindly provided by 
G. Feldmann [12] and HEK293T were cultured at 37°C 
in high glucose Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% Fetal bovine serum 
(FBS) (Invitrogen), 1X vitamin solution (Sigma), 1X non-
essential amino-acid solution (NEAA, Biosource), 1X 
Sodiumpyruvate (Gibco) and 1X Penicillin-Streptomycin 
(LONZA) in a humidified incubator with 5% CO2. 
Transfections were carried out in 6 or 24 well-plates using 
Lipofectamine 3000 kit (Life Techonologies) as described 
by the manufacturer. siRNAs for knockdown of PKCδ 
(sc-36253) and GSK3β (sc-35527) and control siRNA 
(sc-37007) were transfected using INTERFERIN siRNA 
transfection reagent (Polyplus transfection) according to 
manufacturer’s protocol. After 72 h of incubation, proteins 
were extracted for analysis by western blot analysis as 
describe below.
Lentriviral particles production and stable 
clones selection
To generate shYAP expressing stable PK9 and 
PANC1 cells, The pLKO.1-based lentiviral plasmid 
containing YAP shRNA (NM006106) expression cassettes 
were purchased from Sigma-Aldrich. Scramble shRNA 
(Addgene plasmid 1864) was used as a control. Vectors 
were produced in HEK293T cells by co-transfection of 
the different transfer vectors with the packaging plasmid 
pCMV-deltaR8.91 and the VSV envelope-coding plasmid 
pMD2.G. After transfection (48h), lentiviral supernatant 
was filtered through a 0.45 μm syringe filter and used to 
infect YAP into PK9 and PANC1 cells by spinning them 
down with vector containing supernatants for 90 min at 
1500xg at room temperature and leaving them incubate 
overnight at 37°C, then the fresh medium were replaced 
the transduction supernatant. Cells were then further 
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incubated for 72H before collection for WB. Stable silent 
cells were selected using 3 μg/ml puromycin (Sigma) in 
the culture medium.
Immunofluorescence staining and drug screening
PK9 and PANC1 cells were cultured sparsely 
(LOW) and densely (HIGH) onto glass cover slides and in 
96 well-plate for 48 H. Cells were fixed and localization 
of YAP was visualized and nuclei were counterstained 
with DAPI. Immunofluorescence analysis was performed 
using a Zeiss Observer Z1 microscope equipped with 
Apotome module, with a Plan Apochromatic (63X, NA 
1.4) objective. Images were acquired using Zen 1.1 (blue 
edition) imaging software (Zeiss) and assembled with 
Adobe Photoshop CS3. Drug screening, PK9 cells were 
seeded on OptiPlate-96 Black, Black Opaque 96-well 
Microplate (PerkinElmer) at a density of 5000 cells/well, 
to obtain a 70% confluence at the end of the assay. The 
library of known kinase inhibitors was re-suspended in 
DMSO and diluted in PBS 1X. The compounds were 
administrated at the final concentration of 1μM for 24H. 
Cells were fixed as previously described [52], primary 
antibody against YAP (1:500) and secondary fluorophore 
conjugated (Alexa 488) antibody (1:10000) were diluted in 
PBS + BSA 0.2%. DAPI (1.5 μg/ml) in PBS + BSA 0.2% 
was used to detect nuclei. PerkinElmer image plate reader 
Operetta was used for imaging and evaluation. The ratio 
between nuclear and cytoplasmic signal represents the 
mean of single cells for every well and it were normalized 
to untreated control. The Z score was calculated to 
evaluate the significance of results from the screening. Z 
score was calculated as follow: Z = (X–mean)/standard 
deviation. X = normalized sample ratio [51].
Soft-agar and cell migration assay
Each 6-well plate was coated with 1 ml of bottom 
agar (DMEM containing 10% FBS with and 0.7% agar). 
PDAC cell lines, shYAP expressing stable PANC-1 
(1.5x104 cells) were resuspended in 1ml of top agar 
(DMEM containing 10% FBS with and 0.35% agar) 
into each well. Cells were treated with 1ml of BIS I and 
incubated for 2-3 weeks. They were replaced with fresh 
medium with/without treatment every 3 days. PerkinElmer 
image plate reader Operetta was used for imaging and 
colony evaluation.
Cell migration assay. Confluent cells were seeded 
in 6-well plate and wounded by a 200μl pipette tip. 
Media were replaced with BIS I treatment. Images of 
the same field were acquired immediately (0h), after 
24 and 48 hours using a Leica DM IL Led microscope 
(5X magnification). Wounded-open areas were 
photographed and measured at the time of scratch and 
2 days. Relative invaded area was measured using 
Image-J software.
Western blot and sub-cellular fractionation
Cells were treated for 24H then they were 
lysed in cold modified cytosolic lysis buffer (10mM 
HEPES pH 7.0, 10mM KCl, 1mM EDTA, 0.5% 
NP-40, 1mM DTT, and Protease inhibitor cocktail). The 
supernatant containing cytosolic fraction was collected by 
centrifugation at 3000xg for 5 minutes at 4°C. Nuclear 
pellets were then re-suspended in cold modified nuclear 
lysis buffer (10mM HEPES pH 7.0, 400mM NaCl, 
1mM EDTA, 25% Glycerol, 1mM DTT, and Protease 
inhibitor cocktail). The nuclear extract was harvested by 
centrifugation at 12000xg for 15 minutes at 4°C. Equal 
quantities of proteins were separated by electrophoresis 
on a 12% SDS-page gels. The blots were incubated with 
YAP1, Phospho-YAP-1 (Ser127), β-catenin antibodies 
overnight at 4°C. β-actin and Lamin A/C served as the 
loading controls for the cytosolic and nuclear fraction, 
respectively.
Luciferase reporter assay. HEK293T, PK9 and 
PANC1 were seeded in 24 well-plates then indicated 
plasmids were co-transfected using Lipofectamine 3000 
(Invitrogen) or TransIT-LT1 Transfection Reagent (Mirus). 
After transfection (24H), cells were treated with BIS 
family compounds including GF 109203X or BIS I (5μM), 
Go6976 (5μM), Erlotinib (5μM), Lapatinib (5 μM), and 
PMA (1 μM) for 24H. Cells were lysed and luciferase 
activity was assayed using the enhanced luciferase assay 
kit (Promega) following the manufacturer’s instructions. 
The firefly luciferase activity levels were measure and 
normalized to Renilla luciferase activity.
RNA isolation, real-time PCR and ChIP assay
Total RNA was extracted using RNA isolation 
Mini Kit (Agilent Technologies and successively treated 
with RNA-free DNase. RNA was subjected for reverse 
transcription (RT) with iScript reverse transcriptase (Bio-
rad). cDNA was then diluted and 50ng total of cDNA was 
used for qRT-PCR with gene-specific primers using KAPA 
SYBR FAST qPCR master mix (Kapa biosystem) or HOT 
FIREPol EvaGreen qPCR Mix (Solis BioDyne). Relative 
abundance of mRNA was calculated by normalization 
to GAPDH mRNA. The reactions were carried out on 
a CFX96TM real-time system (BIO-RAD). For ChIP 
assay, DNA was extracted by phenol/chloroform/
isoamyl alcohol, ethanol precipitated and re-suspended 
in water. In mRNA expression experiments, Ct values 
of every gene were normalized to the housekeeping 
GAPDH, while in ChIP assays, the normalization were 
calculated by the following formula: (X–IgG)/INPUT, 
where X is the Ct of the sequence of interest derived 
from the immunoprecipitated DNA bound to the protein 
of interest; IgG is the Ct of the same sequence derived 
from the DNA immunoprecipitated with an irrelevant 
antibody and INPUT is the Ct derived from the total DNA 
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before immunoprecipitation. Primers for quantitative real 
time PCR (for ChIP assay) were obtained from MWG/
Operon, with the following sequences: Forward: 5′ 
TTGGTGCTGGAAATACTGCG 3′, Reverse: 5′ CTCA 
GCGGGGAAGAGTTGTT 3′. Other primers used in this 
work are listed in Supplementary Table S2.
Cell cycle and real-time cell proliferation assay
Cells were incubated in a 96-well plate (200 ul 
of medium/well) with the tested compounds for 24H 
and cell viability was quantitatively determined by a 
colorimetric MTT assay. In brief, MTT (5mg/ml) at 
10% volume of culture media was added to each well 
and cells were further incubated for 2H at 37°C. Then 
supernatant containing MTT was replaced by 100μl 
of DMSO to dissolve formazan. Absorbance was then 
determined at 565nM by microplate reader. Cell survival 
was calculated and EC50 values were determined. Cell 
cycle was measured by FACS analysis at 24H after 
treatment using propidium iodide (PI) staining. Real time 
cell proliferation assay: PK9 were seeded 5000 cells/well 
in E-plates (Roche), in triplicates. The cell growth curves 
were automatically recorded on the xCELLigence System 
(Roche) in real time. The cell attachment was monitored 
every 15 minutes by a cell electronic system. The doubling 
times were calculated according with cell index. The 
cell index is an arbitrary unit for displaying inpedence. 
SCR or siRNAs transfection PK9 cells were performed 
by replacing cell medium, including untreated control to 
operate at the same working conditions.
Two-dimensional electrophoresis
The experiment was performed according to previous 
protocols [52]. Proteins were extracted using a lysis buffer 
(8M urea, 4% CHAPS, 50mM dithioerythritol and 0,0002% 
Bromophenol blue) and rehydrated with 8M urea, 2% 
CHAPS, 20mM dithioerythritol, 0.8% IPG buffer, carrier 
ampholytes pH 6-11 linear. The first dimension isoelectric 
focusing (IEF) was performed in immobiline dry strips (GE) 
with a pH range from 7 to 4. IEF was performed on IPGphor 
(GE) according to the manufacturer recommendations. The 
gels were then equilibrated in 6M urea, 3% SDS, 375mM 
Tris pH 8.6, 30% glycerol, 2% DTE and then incubated 
with 3% iodoacetamide (IAA) and traces of bromophenol 
blue (BBP). The second dimension was performed using an 
8% SDS-PAGE gel. Transfer and detection were carried out 
as previously described.
Statistical analysis
The Data are presented as mean±SD and the 
standard deviation of the mean (SD) in this study were 
calculated for 3 replicates in each of the 3 independent 
experiments. Statistical comparisons were assessed with 
analysis of Student’s test and One-way ANOVA calculated 
with GraphPad Prism version 5.0 for Windows (GraphPad 
Software). P<0.05 was considered statistically significant 
difference and P<0.01, and P<0.001 were considered as 
highly significant difference.
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